The clinician's perspective on sarcoma pathology reporting: Impact on treatment decisions?

Pathology

Volumn 46, Issue 2, 2014, Pages 121-125

  Blay, Jean Yves ^a,b,c   Derbel, Olfa ^a   Ray Coquard, Isabelle ^a  

^a CENTRE LÉON BÉRARD   (France)

^b CENTRE DE RECHERCHE EN CANCÉROLOGIE DE LYON   (France)

^c UNIVERSITÉ LYON 1   (France)

Author keywords

Adjuvant; Histology; Margins; Multidisciplinary; Sarcoma; Surgery; Treatment

Indexed keywords

ARTICLE; CANCER GRADING; DECISION MAKING; HUMAN; METHODOLOGY; MOLECULAR PATHOLOGY; PATHOLOGY; PHYSICIAN ATTITUDE; PRACTICE GUIDELINE; SARCOMA;

DECISION MAKING; HUMANS; NEOPLASM GRADING; PATHOLOGY, MOLECULAR; PHYSICIAN'S ROLE; PRACTICE GUIDELINES AS TOPIC; SARCOMA;

EID: 84896754213     PISSN: 00313025     EISSN: 14653931     Source Type: Journal    
DOI: 10.1097/PAT.0000000000000052     Document Type: Article

References (27)

1. Fletcher CDM, Bridge JA, Hogendoorn PCW, Mertens F. World Health Organization. Pathology and Genetics of Tumours of Soft Tissue and Bone. Lyon: IARC Press, 2013.
2. Ducimetière F., Lurkin A, Ranchère-Vince D, et al. Incidence of sarcoma histotypes and molecular subtypes in a prospective epidemiological study with central pathology review and molecular testing. PLoS One 2011; 6: e20294.
3. Corless CL, Barnett CM, Heinrich MC Gastrointestinal stromal tumours: origin and molecular oncology. Nat Rev Cancer 2011; 11: 865-78.
4. Blay JY, Le Cesne A, Cassier PA, Ray-Coquard IL. Gastrointestinal stromal tumors (GIST): a rare entity, a tumor model for personalized therapy, and yet ten different molecular subtypes. Discov Med 2012; 13: 357-67.
5. ESMO/European Sarcoma Network Working Group. Soft tissue and visceral sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012; 23 (Suppl 7): vii92-9.
6. The ESMO/European Sarcoma Network Working Group. Gastrointestinal stromal tumors: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2012; 23 (Suppl 7): vii49-55.
7. Blay JY, van Glabbeke M, Verweij J, et al Advanced soft-tissue sarcoma: a disease that is potentially curable for a subset of patients treated with chemotherapy. Eur J Cancer 2003; 39: 64-9.
8. Italiano A, Mathoulin-Pelissier S, Cesne A.L., et al Trends in survival for patients with metastatic soft-tissue sarcoma. Cancer 2011; 117: 1049-54.
9. Cassier PA, Labidi-Galy SI, Heudel P., et al Therapeutic pipeline for softtissue sarcoma. Expert Opin Pharmacother 2011; 12: 2479-91.
10. Blay JY, Derbel O, Ray-Coquard I. Do our current clinical trial designs help to guide clinical practice? Am Soc Clin Oncol Educ Book 2013: 381-5.
11. Barretina J, Taylor BS, Banerji S, et al Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy. Nat Genet 2010; 42: 715-21.
12. Ray-Coquard I., Montesco MC, Coindre J.M., et al for the Conticanet groupSarcoma: concordance between initial diagnosis and centralized expert review in a population-based study within three European regions. Ann Oncol 2012; 23: 2442-9.
13. Neuville A, Chibon F, Coindre J-M. Grading of soft tissue sarcomas: from histological to molecular assessment. Pathology 2014; 46: 113-20.
14. Cassier PA, Kantor G, Bonvalot S., et al Adjuvant radiotherapy (adj RT) for extremity and trunk wall atypical lipomatous tumor/well-differentiated LPS (ALT/WD-LPS): A French Sarcoma Group (GSF-GETO) study. J Clin Oncol 2013; 31 (Suppl): 10582 (Abstr).
15. Gortzak E, Azzarelli A, Buesa J., et al EORTC Soft Tissue Bone Sarcoma Group and the National Cancer Institute of Canada Clinical Trials Group/Canadian Sarcoma Group. A randomised phase II study on neo-adjuvant chemotherapy for 'high-risk' adult soft-tissue sarcoma. Eur J Cancer 2001; 37: 1096-103.
16. Cassier PA, Fumagalli E, Rutkowski P., et al European Organisation for Research and Treatment of Cancer. Outcome of patients with plateletderived growth factor receptor alpha-mutated gastrointestinal stromal tumors in the tyrosine kinase inhibitor era. Clin Cancer Res 2012; 18: 4458-64.
17. Weger C, Frings A, Friesenbichler J., et al Osteolytic lesions of the calcaneus: results from a multicentre study. Int Orthop 2013; 37: 1851-6.
18. Derbel O, Cropet C, Meeus P., et al Adhesion to clinical practices guidelines (CPGs) and role on survival for soft tissue sarcoma patients. Analysis of a population based cohort from Rhone-Alpes region. Ann Oncol 2012; (Suppl): 2955 (Abstr).
19. Bonvalot S, Rivoire M, Castaing M., et al Primary retroperitoneal sarcomas: a multivariate analysis of surgical factors associated with local control. J Clin Oncol 2009; 27: 31-7.
20. Sarcoma Meta-analysis Collaboration. Adjuvant chemotherapy for localised resectable soft-tissue sarcoma of adults: meta-analysis of individual data. Sarcoma Meta-analysis Collaboration. Lancet 1997; 350: 1647-54.
21. Woll PJ, Reichardt P, Le Cesne A, et al EORTC Soft Tissue and Bone Sarcoma Group and the NCIC Clinical Trials Group Sarcoma Disease Site Committee. Adjuvant chemotherapy with doxorubicin, ifosfamide, and lenograstim for resected soft-tissue sarcoma (EORTC 62931): a multicentre randomised controlled trial. Lancet Oncol 2012; 13: 1045-54.
22. Le Cesne A., Van Glabbeke M, Woll PJ, et al The end of adjuvant chemotherapy (adCT) era with doxorubicin-based regimen in resected high-grade soft tissue sarcoma (STS): Pooled analysis of the two STBSG-EORTC phase III clinical trials. J Clin Oncol 2008; 26 (Suppl): 10525 (Abstr).
23. Ray-Coquard I., Blay JY, Italiano A, et al Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, welldifferentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study. Lancet Oncol 2012; 13: 1133-40.
24. Dickson MA, Tap WD, Keohan M.L., et al Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified well-differentiated or dedifferentiated liposarcoma. J Clin Oncol 2013; 31: 2024-9.
25. Chibon F, Lagarde P, Salas S., et al Validated prediction of clinical outcome in sarcomas and multiple types of cancer on the basis of a gene expression signature related to genome complexity. Nat Med 2010; 16: 781-7.
26. Lagarde P, Pérot G, Kauffmann A., et al Mitotic checkpoints and chromosome instability are strong predictors of clinical outcome in gastrointestinal stromal tumors. Clin Cancer Res 2012; 18: 826-38.
27. de Vijver M.J., He YD, van't Veer LJ, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002; 347: 1999-2009.